RepliCel Life Sciences Inc (OTCMKTS:REPCF) posted about the granting of a key patent in the U.S. covering components of the multi-needle dermal injection product. In the advancement of cell treatment offerings for the cure of sun-damaged or aging skin and pattern baldness, the dermatology team identified a requirement for superior dermal injection know-how that boasts new levels of control and accuracy to any substances put into a person’s skin.
RepliCel Life Sciences posted that the patent released by the USPTO relates to know-how intended to permit repeatable consistency and unmatched control of product deposition and needle measure. The patent links to the element used to numb the skin prior to injection with the deliberate effect of lowering, if not eliminating, the need for local numbing before aesthetic injection course.
The first device being formulated under this patent is ‘RCI-02’ which is made for injecting soft tissue fillers. If the recent statistics report is seen, the count of minimally invasive cosmetic courses performed countrywide last year exceled 11 million; over 80% were marked wrinkle treatments and hyaluronic acid filler doses, totaling an expenditure of around $3 billion. ‘RCI-02’ demonstrates the nearest-term commercial chance for the firm, which it wants to keep market-ready and in the extent of a commercial associate and co-development licensee in 2018.
RepliCel Life Sciences posted that the device is being progressed for the injection of ‘RCS-01’ and ‘RCH-01’ offerings. Future versions will cover the scope of other injectable such as drugs, fat grafts, biologics, vaccines, etc.
Lee R. Buckler, who is the CEO of RepliCel, posted that they are confident their patent estate for cell treatment as well as injection devices give their offerings a long-term industry exclusivity. The allowance of patent is a key addition to their formidable IP portfolio, which will further create value for stockholders.